Achieve Life Sciences

Q2 FY2026 EarningsQ2 FY26 results significantly missed consensus on profitability metrics, primarily due to a massive non-cash warrant liability charge. Net loss of $74.8M was 464% wider than the $13.3M expected, resulting in a GAAP EPS of -$0.80 vs. -$0.16 consensus. Despite the earnings miss, the company bolstered its balance sheet through a $354M private placement, ending the quarter with $187.3M in cash. Strategic focus remains on the Q4 2026 NDA resubmission and H1 2027 potential FDA approval.